Idarubicin（IDA）

DRUG2 trials

Sponsors

Nanfang Hospital, Southern Medical University, Beijing 302 Hospital

Conditions

Acute Myeloid LeukemiaAutologous Hematopoietic Stem Cell TransplantationConditioning

Phase 2

IDA+BUCY vs BUCY Conditioning Regimen for Intermediate-risk AML Undergoing Auto-HSCT

CompletedNCT02671708

Nanfang Hospital, Southern Medical UniversityAcute Myeloid Leukemia, Autologous Hematopoietic Stem Cell Transplantation, Conditioning

Start: 2016-01-31End: 2020-02-28Updated: 2020-03-03

Venetoclax-containing Therapy Combined With Microtransplant for Newly Diagnosed AML

RecruitingNCT07078591

Beijing 302 HospitalAcute Myeloid Leukemia

Start: 2025-06-20End: 2031-06-30Target: 50Updated: 2025-07-28

Related Papers

Idarubicin plus <scp>BuCy</scp> versus <scp>BuCy</scp> conditioning regimens for intermediate‐risk acute myeloid leukemia in first complete remission undergoing <scp>auto‐HSCT</scp>: An open‐label, multicenter, randomized phase 3 trial

American Journal of Hematology2023-01-015 citations